scPharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
14/11/2024 04:05
* scPharmaceuticals Inc SCPH.OQ reported a quarterly
adjusted
loss of 75 cents per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -41 cents. The mean expectation of six analysts for the
quarter was for a loss of 30 cents per share. Wall Street
expected results to range from -33 cents to -28 cents per share.
* Revenue rose 164.1% to $10.03 million from a year ago;
analysts
expected $10.80 million.
* scPharmaceuticals Inc's reported EPS for the quarter was a
loss
of 75 cents.
* The company reported a quarterly loss of $35.11 million.
* scPharmaceuticals Inc shares had fallen by 13.8% this
quarter and lost 37.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 11.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for scPharmaceuticals
Inc is 19.00
This summary was machine generated from LSEG data November 14 at
04:05 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.30 -0.75 Missed
Jun. 30 2024 -0.41 -0.44 Missed
Mar. 31 2024 -0.44 -0.36 Beat
Dec. 31 2023 -0.42 -0.35 Beat